Director
CHOP
AM24-SN-06-L - Operationalizing Delivery of Gene Therapy for Sickle Cell Disease
Sunday, October 20, 2024
8:15 AM - 9:15 AM
Disclosure(s): Agios Pharmaceuticals: Consultant/Advisory Board (Ongoing), Grant/Research Support (Ongoing); Bluebird Bio: Consultant/Advisory Board (Ongoing), Grant/Research Support (Ongoing); Celgene/Bristol Myers Squibb: Consultant/Advisory Board (Terminated); Chiesi: Consultant/Advisory Board (Ongoing); Editas Medicine: Grant/Research Support (Ongoing); Imara: Consultant/Advisory Board (Terminated), Grant/Research Support (Terminated); NovoNordisk/Forma: Consultant/Advisory Board (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant/Advisory Board (Terminated); Regeneron: Consultant/Advisory Board (Terminated); Sangamo Therapeutics: Grant/Research Support (Terminated); Vertex Pharmaceuticals: Consultant/Advisory Board (Ongoing), Grant/Research Support (Ongoing)